斯派格拉斯制药

关于 SpyGlass Pharma

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which 从事 the 开发 of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was 成立 in January 2019 by Malik Y. Kahook and Glenn Sussman and is 总部位于 in Aliso Viejo, CA.

成立时间

2019

首席执行官

Mr. Patrick H. Mooney

员工人数

65

总部地址

Aliso Viejo, California, United States of America

财年结束日

12-31

官方网站

spyglasspharma.com

公司概况

交易所

US

股票代码

SGP

市值排名

#3415

上市日期

2026-02-06

市值

802.75M

流通市值

155.91M

总股数

33.45M

流通股数

6.50M

行业与主题板块

浏览全部行业与主题板块